BridgeBio Pharma, Inc. research snapshot
BBIO AI stock analysis currently views BridgeBio as a commercial-stage genetic-disease company whose near-term economics depend on Attruby while future value also hinges on late-stage pipeline execution. At the August 2, 2026 cutoff, the latest public close was $80.09, verified market capitalization was about $15.66 billion, and cash and marketable securities were $940.19 million at March 31. Revenue growth is real, but net losses, about $2.49 billion of debt, deferred royalty obligations, clinical and regulatory uncertainty, and the dilution overhang from a $1 billion preferred equity raise and a pending secondary share sale keep this a high-risk setup. This BBIO AI stock analysis uses scenarios instead of a certain price prediction and is for informational use, not investment advice.
Current price
$80.09 at the July 31, 2026 close
Market cap
$15.66 billion
AI score
57 / 100
Rating
Commercial-stage rare-disease company with strong Attruby growth, a fortified balance sheet, and high pipeline, leverage, and valuation risk
Trend status
Above the 50-day and 200-day averages, but momentum cooled from the July peak after a roughly 11% pullback
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | BridgeBio discovers, develops, and commercializes medicines for genetic diseases. Customers and payers pay when an approved therapy demonstrates sufficient clinical value, access, and persistence, which Attruby is now showing in ATTR-CM. | Medium |
| Moat | The moat rests on patents, scientific know-how, clinical evidence, regulatory exclusivity, rare-disease expertise, and commercial execution. It must be earned and renewed by each program rather than assumed from the platform label. | Medium-low |
| Management | Management closed a $1 billion preferred equity raise in July 2026 to fund upcoming launches while keeping a $500 million repurchase authorization. The central test is converting capital into durable product economics and advancing the pipeline efficiently. | Medium |
| Financial trend | TTM revenue was $579.96 million, including about $506.23 million of net product revenue. Q1 2026 revenue reached $194.52 million, but the net loss attributable to common stockholders was $164.04 million and free cash flow was negative. | High |
| Valuation | At $80.09, financial_rigor.py confirmed a negative PE and FCF yield because BBIO remains loss-making, with negative book value of about -$11.64 per share. PS was about 27x TTM revenue, so the market value mostly reflects Attruby durability and pipeline expectations. | Medium |
| Technical trend | The August 2, 2026 snapshot put BBIO above its 50-day average of $74.12 and 200-day average of $71.38, with RSI back near 50.90 after the extended reading in early July, and the price roughly 11% below the July peak near $91.67. | Medium |
| Risk level | Risk is high. Attruby uptake, pricing and reimbursement, competition, trial data, FDA decisions on BBP-418 and encaleret, cash burn, debt, deferred royalty obligations, dilution, short interest near 13% of shares outstanding, and a sharp valuation reset can all change the thesis quickly. | High |
| AI confidence | Reported data are well supported, but AI cannot reliably forecast trial success, regulatory outcomes, payer behavior, future financing, dilution, or the market response to new evidence. | High data confidence |
| Investment certainty | Investment certainty is low to medium because current commercial momentum is observable while the long-term earnings path, pipeline value, and capital burden remain uncertain. | Low-medium |
BBIO AI stock forecast
The BBIO AI stock forecast is scenario-based, not a point target. The mandatory three-scenario EPS calculation produces non-economic negative values because current EPS is negative, so it is not used as a valuation target. The ranges below frame commercial and pipeline outcomes around the July 31, 2026 close of $80.09.
$100 to $125
More likely if Attruby demand and persistence remain strong, BBP-418 is approved and launches in late 2026, encaleret and infigratinib advance through review and launch, international uptake expands, and the preferred equity and any secondary sale are absorbed without pressure.
$65 to $100
More likely if Attruby growth continues but investors retain a large discount for losses, debt, royalty obligations, the pending secondary share sale, pipeline timing, reimbursement, competition, and the uncertainty of future program economics.
$40 to $65
More likely if Attruby growth slows, access or competition pressures revenue, a material trial or regulatory event disappoints, dilution increases, cash needs rise, or the market re-rates high-multiple biopharma assets lower.
BBIO AI technical analysis
BBIO AI technical analysis uses the latest public snapshot available at the August 2, 2026 cutoff: $80.09 at the July 31 close, 50-day moving average of $74.12, 200-day moving average of $71.38, RSI of 50.90, beta of 0.95, 20-day average volume of about 3.30 million shares, and a 52-week range of $42.09 to $93.42. This static page does not fetch request-time data. Confirm every level in a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $80.09 | Public closing quote on July 31, 2026. Refresh the quote before any decision. |
| Near support | $74.12 | Reported 50-day moving average at the cutoff. A sustained loss would weaken the intermediate trend. |
| Deeper support | $71.38 | Reported 200-day moving average at the cutoff. Moving averages change daily and require a live check. |
| Near resistance | $90 to $93.42 | The July high near $91.67 and the 52-week high of $93.42 form a resistance zone after the pullback. |
| Moving averages | 50-day $74.12; 200-day $71.38 | The cutoff quote was above both averages, supporting the trend while it remains live-chart dependent. |
| Momentum | RSI 50.90 | Momentum cooled to a neutral reading after the extended RSI in early July, which removes some overbought pressure but also reflects weaker short-term momentum. |
| Volume | 20-day average about 3.30 million shares | Use above-average volume and relevant company news to validate a breakout or reversal. |
| Volatility | 5-year beta 0.95 | Event-driven biopharma moves can exceed historical beta, especially around data, FDA, reimbursement, earnings, and financing updates. Next earnings are scheduled for August 14, 2026. |
| Invalidation | Decisive close below the live 50-day average | For a trend-following framework, a confirmed break below the live 50-day average near $74.12 is an invalidation condition, not a personal sell instruction. |
BBIO AI trading strategy
The BBIO AI trading strategy is a rules-based research framework, not personalized advice. It combines live price confirmation with Attruby prescriptions and persistence, revenue mix, gross margin, R&D and SG&A, cash, debt, royalty obligations, share count, the pending secondary sale, FDA calendars, trial data, and competitor developments.
Wait for BBIO to hold above the live 50-day average and for any advance toward the $90 to $93.42 zone to have volume confirmation and an unchanged commercial or pipeline thesis. Check trial, FDA, earnings, and financing dates before relying on a chart pattern.
Define risk before entry. A failed breakout or decisive close below the live 50-day average near $74.12 can invalidate this setup.
If BBIO pulls back toward the moving averages without a negative commercial, clinical, regulatory, financing, or dilution update, wait for stabilization and compare the move with Attruby sales, cash, debt, royalty obligations, and program timelines.
Do not average down because a share price fell. The setup fails if support breaks alongside weaker demand, adverse data, delayed approval, or a higher funding requirement.
Track Attruby net product revenue, patient and prescriber trends, BEYONTTRA royalties, gross margin, operating expenses, cash and marketable securities, debt and deferred royalty obligations, preferred equity conversion, secondary sale execution, diluted shares, FDA decisions, trial readouts, payer access, and competitor treatment data.
Refresh all scenarios after material earnings, clinical data, an FDA decision, a financing or royalty transaction, a secondary offering, a program discontinuation, or a large price gap. Avoid stale technical levels around binary events.
Investment research summary
BridgeBio applies genetic science to discover, develop, and commercialize medicines for patients with significant unmet need. Its economic value depends on generating evidence, securing approval and access, and turning approved therapies such as Attruby into persistent product revenue.
Relevant protections are patents, scientific know-how, clinical data, regulatory exclusivity, rare-disease focus, specialist relationships, and commercial execution. These advantages matter only if each medicine shows a durable clinical and economic case relative to alternatives in ATTR-CM and other indications.
The thesis can fail if Attruby growth slows, payer access narrows, a competing therapy gains share, clinical data disappoint, safety or manufacturing issues emerge, the FDA delays or rejects BBP-418 or encaleret, cash needs rise, dilution expands, or debt and royalty obligations constrain flexibility.
The management test is capital allocation under uncertainty: protect commercial execution, fund the highest-value programs, control overhead, manage obligations, use the $1 billion preferred equity wisely, and keep repurchases from compromising the balance sheet or development runway.
Genetic medicine and rare-disease treatment can create substantial value when evidence, diagnosis, reimbursement, and specialist adoption align. The path is discontinuous and shaped by trial design, regulation, payer access, manufacturing, competition, and patient persistence.
The verified $15.66 billion market capitalization reflects current Attruby momentum plus expectations for pipeline assets. With negative trailing EPS and free cash flow and negative book value, a margin of safety cannot be read from PE, PB, or FCF multiples. It requires conservative assumptions about demand, program success, spending, financing, and obligations.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BBIO price and market capitalization | $80.09 close on July 31, 2026; $15.66 billion market capitalization; 195.49 million shares outstanding. financial_rigor.py verified price times shares with a 0.02% difference from reported market cap. | StockAnalysis statistics, verified with financial_rigor.py | August 2, 2026 |
| TTM revenue and net loss | TTM revenue was $579.96 million, including about $506.23 million of net product revenue; TTM net loss attributable to common stockholders was about $721.55 million and EPS was -$3.74. | StockAnalysis financials, cross-checked with BridgeBio filings | August 2, 2026 |
| FY2025 revenue and net loss | $502.08 million revenue, up 126.26% from $221.90 million in 2024, including $362.37 million of Attruby net product revenue; FY2025 net loss attributable to common stockholders was -$724.93 million. | BridgeBio 2025 Form 10-K, cross-checked with StockAnalysis | August 2, 2026 |
| Q1 2026 revenue and net loss | $194.52 million total revenue, including $180.60 million of Attruby net product revenue; net loss attributable to common stockholders was $164.04 million and EPS was -$0.84. | BridgeBio Q1 2026 results and Form 8-K | August 2, 2026 |
| Cash, debt, and book value | $940.19 million in cash and short-term investments at March 31, 2026; total debt of about $2.49 billion; net cash of about -$1.55 billion; book value of about -$11.64 per share. | StockAnalysis balance sheet and statistics | August 2, 2026 |
| Preferred equity raise | On July 1, 2026, BridgeBio announced up to $1 billion of Series A Cumulative Convertible Participating Preferred Stock, with Sixth Street investing $800 million and HealthCare Royalty investing $133.9 million, at an initial conversion price of $137.79 per share. | BridgeBio press release, July 1, 2026 | August 2, 2026 |
| Regulatory and pipeline update | FDA accepted the encaleret NDA for ADH1 with a PDUFA target action date of May 8, 2027; BBP-418 NDA was accepted with Priority Review and a PDUFA target action date of November 27, 2026; Phase 3 PROPEL 3 of oral infigratinib in achondroplasia met its primary endpoint and was published in NEJM. | BridgeBio press releases, June-July 2026 | August 2, 2026 |
| Secondary share sale filing | BridgeBio filed in late July 2026 to sell about 24.63 million shares of common stock for selling stockholders, adding a potential dilution overhang to the shares. | BridgeBio SEC filing and news reports | August 2, 2026 |
| Technical snapshot | 50-day average $74.12; 200-day average $71.38; RSI 50.90; 20-day average volume about 3.30 million; beta 0.95; 52-week range $42.09 to $93.42; short interest near 25.75 million shares. | StockAnalysis statistics | August 2, 2026 |
This BBIO page is an informational research tool, not investment advice, a recommendation, or a guarantee of performance. Forecast ranges are scenarios based on available dated data and assumptions that can be wrong. Verify live market data and primary filings before making an investment decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
